Report from Orexo AB’s annual general meeting, 13 April 2021. 13 April 2021 · Press Release · Regulatory. Orexo publishes Annual Report for 2020. 23 March 2021 · RDV · Regulatory. Orexo publishes prospectus and applies for admission to trading of corporate bonds. 16 March 2021

6 Apr 2021 Performance at Orexo AB (publ) ( STO:ORX ) has been reasonably good and CEO Nikolaj Sørensen has done a decent job of

It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. Orexo is improving the lives of people suffering from addiction disorders and mental illness. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities Orexo AB (publ) is a public limited liability company registered in Sweden with registration number 556500-0600, having its registered address at P.O. Box 303, SE-751 05, Uppsala, Sweden.

VAT No. Orexo AB har 54 anställda och gjorde ett resultat på 219 000 KSEK med omsättning 609 000 KSEK under 2019. Bolaget hade då en omsättningstillväxt på 29,3 %. Orexos vinstmarginal låg vid senaste årsbokslutet på 37,9 % vilket ger Orexo placeringen 81 084 i Sverige av totalt 645 618 aktiebolag. Den här länken kommer att omdirigera dig till en webbplats som underhålls av annan part än Orexo.

2021-04-13 14:15:00 Kommuniké från årsstämma, Kommuniké från Orexo AB:s årsstämma Detta innehåll är endast för prenumeranter. Registrera dig för en kostnadsfri provperiod. Registrering förbinder dig inte till att köpa Zenostock.

Head of Pharmaceutical Development & IP at Orexo AB since 2016 and prior to that extensive experience of drug discovery and development, as well as patent prosecution and litigation, from various key positions at Biolipox AB and Orexo AB. Holds 1,741 shares and stock options/share awards entitling to 45,896 shares. 1. 1 As of December 31, 2020

Ticker: ORX Aktiekurs: 46,35 Storlek: Small Cap Sektor: Hälsovård Risk: Orexo aktiekurser First north aktiekurser Orexo (ORX) - Köp Tredje AP-fondens innehav i Orexo AB går från 5,03% till 3,94% av röster och kapital efter bolagets nyemission. För mer information kontakta Advisory · Press room.

Orexo's policy is to drug test all prospective employees and a negative drug test is a prerequisite for Postadress. Orexo AB. Virdings allé 32. 75450 Uppsala

Its pipeline comprises of Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces the company will collaborate with ApexB.io and Magellan Rx Management to further research on the use of modia™, a digital therapeutic Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health.

The annual general meeting in Orexo AB (publ) on 13 April 2021 resolved, in accordance with the nomination committee&a Orexo Q1 2021 Interim Report Quarterly Report - Orexo Q1 2021 Interim Report ORXOY : Orexo AB. SEC.report Stock analysis for Orexo AB (ORXOF:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Report from Orexo AB's extraordinary general meeting, 19 May 2020.
Bi utvecklare lön

På allabolag.se hittar du företagsinformation om Orexo AB. allabolag.se ger alla tillgång till bokslut, befattningshavare, kreditupplysningar, adresser och annan företagsinformation. ©2020 Orexo AB (publ.) – Med ensamrätt. Kontakt Den här länken kommer att omdirigera dig till en webbplats som underhålls av annan part än Orexo. Orexo: Antal aktier och röster i Orexo Uppsala - 29 maj 2020 - Antalet aktier och röster i Orexo AB (publ) har förändrats på grund av indragning av 842 971 C-aktier, vilket beslutades på bolagets årsstämma den 16 april 202 Orexo är ett svenskt läkemedelsföretag med fokus på terapiområdena smärta och inflammation, grundat med venturekapital från HealthCap.

Orexo publicerar årsredovisning för 2020. 23 mars 2021 · RDV · Regulatoriskt. Orexo offentliggör prospekt och ansöker om upptagande till handel av företagsobligationer. 16 mars 2021 Report from Orexo AB’s annual general meeting, 13 April 2021.
Kiralitet uttal

Senaste nytt om Orexo aktie. Orexo komplett bolagsfakta från DI.se. Orexo AB, 1,20%, 1,20%. Evli Funds, 1,00%, 1,00%. Nordnet Pensionsförsäkring AB, 1,00

The Company was formed on 18 November 1994 and registered with the Swedish Companies Registration Office on 25 November 1994. References to “Orexo” or the “Group” refer in this Prospectus to Orexo AB (publ) and its subsidiaries from time to time, unless indicated by the context. References to “SEK” refer to Swedish Kronor.

Hvordan bli kameramann

Kommuniké från Orexo AB:s årsstämma den 13 april 2021: 13-04: Report from Orexo AB's annual general meeting, 13 April 2021: 23-03: Orexo publishes Annual Report for 2020: 23-03: Orexo publicerar årsredovisning för 2020: 17-03: Orexo continues to strengthen IP rights for ZUBSOLV® 17-03: Orexo fortsätter stärka patentskyddet för ZUBSOLV

· Drug Product and Patent(s)-in-Suit: Suboxone® and Subutex® (buprenorphine); U.S. Patent No. · Nature of the Case 6 Apr 2021 Performance at Orexo AB (publ) ( STO:ORX ) has been reasonably good and CEO Nikolaj Sørensen has done a decent job of Report from Orexo AB’s annual general meeting, 13 April 2021 13 April 2021 · Press Release · Regulatory 23 March 2021 · RDV · Regulatory Kommuniké från Orexo AB:s årsstämma den 13 april 2021 13 april 2021 · Pressmeddelande · Regulatoriskt 23 mars 2021 · RDV · Regulatoriskt Get the latest Orexo AB (ORX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Orexo AB P.O. Box 303 751 05 Uppsala Sweden. E-mail: info@orexo.com Phone: 46-18-780-88-00 Fax: 46-18-780-88-88. VAT No. Find the latest Orexo AB (ORX.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities Orexo AB operates as a pharmaceutical company. The Company develops improved drugs based on drug delivery technologies, as well as focuses on opioid addiction and pain.

Election of the board of directors and auditor. The annual general meeting in Orexo AB (publ) on 13 April 2021 resolved, in accordance with the nomination committee's proposal, that the number of board members shall be eight with no deputy board members. James Noble, Staffan Lindstrand, David Colpman, Henrik Kjær Hansen, Kirsten Detrick, Fred Wilkinson, Mary Pat Christie and Charlotte …

På allabolag.se hittar du företagsinformation om Orexo AB. allabolag.se ger alla tillgång till bokslut, befattningshavare, kreditupplysningar, adresser och annan företagsinformation. Headquarter. Orexo AB P.O. Box 303 751 05 Uppsala Sweden. E-mail: info@orexo.com Phone: +46 (0)18 780 88 00 VAT No. SE556500-060001 Visiting address. Rapsgatan 7E, Uppsala, Sweden Since 2013, Orexo has been commercializing its key product ZUBSOLV®, for treatment of opioid dependence, in the US. The company's own sales force covers large parts of the country and in 2020 an important milestone was reached when ZUBSOLV´S total gross sales, since start, exceeded USD 1 billion. Orexo AB har 54 anställda och gjorde ett resultat på 219 000 KSEK med omsättning 609 000 KSEK under 2019.

Report from Orexo AB's annual general meeting, 13 April 2021. Election of the board of directors and auditor. The annual general meeting in Orexo AB (publ) on 13 April 2021 resolved, in accordance with the nomination committee&a Orexo Q1 2021 Interim Report Quarterly Report - Orexo Q1 2021 Interim Report ORXOY : Orexo AB. SEC.report Stock analysis for Orexo AB (ORXOF:OTC US) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Report from Orexo AB's extraordinary general meeting, 19 May 2020. Publicerad: 2020-05-19 (Cision) Kommuniké från Orexo AB:s extra bolagsstämma den 19 maj 2020.